Monday May 9, 2016
Three recent "impressive" stories
Chairman: F. Pane
A. Younes
Brentuximab Vedotin in lymphomas
M.S. Topp
Blinatumumab in ALL
C.H. June
CAR T-cells
Session I
Classical Ph1-neg myeloproliferative neoplasms
Chairmen: F. Passamonti, A.M. Vannucchi
R.A. Mesa
Status of the art of treatment
F. Passamonti
Ruxolitinib in myelofibrosis
A.M. Vannucchi
Ruxolitinib in polycitemia vera
F. Cervantes
New JAK2 inhibitors in MPNs and combination therapy
H.C. Hasselbalch
Interferons in MPNs
G. Barosi
Newer drugs for myelofibrosis
Session II
Hodgkin's lymphoma
Chairmen: P. Borchmann, P.L. Zinzani
P. Borchmann
Status of the art of treatment
A. Younes
Nivolumab
S. Schuster
Pembrolizumab
A.J. Moskowitz
Bendamustine
A. Younes
New Combo-steps
Session III
Chronic myeloid leukemia
Chairmen: M. Gobbi, G. Rosti
M. Baccarani
Status of the art of treatment
F. Castagnetti
Nilotinib-based treatments and ABL001
G. Saglio
Dasatinib and combination
T.H. Brummendorf
Bosutinib
G. Rosti
Ponatinib
Tuesday, May 10, 2016
Two "transversal on lymphomas" drugs
Chairman: P. Corradini
B.D. Cheson
Bendamustine
T.E. Witzig
Lenalidomide
Session IV
Non-Hodgkin's lymphoma (I)
Chairmen: B.D. Cheson, A. Pinto
B.D. Cheson
Status of the art of treatment
N.H. Fowler
Ublituximab
A. Thall
anti-4-1BB
M. Ogura
Mogamulizumab
A. Kolstad
177Lu-HH1 (Betalutin)
M.G. Kauffman
Selinexor
R. Pettengell
Pixantrone
Session V
Non-Hodgkin's lymphoma (II)
Chairmen: N.H. Fowler, M. Martelli
S. Rule
Venetoclax
S. de Vos
Idelalisib
S. Rule
Ibrutinib
M. Dreyling
Copanlisib
S. Le Gouill
Acalabrutinib
V. Ribrag
Tazemetostat
Session VI
Chronic Lymphocitic Leukemia
Chairmen: A. Cuneo, R. Foà
S.M. O'Brien
Status of the art of management
P. Hillmen
Ibrutinib
S.E. Coutré
Idelalisib
P. Hillmen
Venetoclax
S.M. O'Brien
Acalabrutinib
P. Porcu
Duvelisib
Wednesday, May 11, 2016
Session VII
Multiple myeloma
Chairmen: M. Cavo, S. Lonial
A. Palumbo
Status of the art of treatment
P.G. Richardson
Modelling of disease evolution:
what have we learned and
how can we drive future treatment strategies?
P.G. Richardson
Immune checkpoint inhibitors and immune-based therapies
P. Moreau
New insights into optimal use of
PIs and IMiDs based on sensitizing targets and biomarkers
S. Lonial
Histone deacetilase and kinase inhibitors
S.K. Kumar
Is personalized therapy ready for primetime?
Other two "interesting issues"
Chairmen: A. Genazzani, P.L. Zinzani
A. Genazzani
Rituximab biosimilars
M. Spina
The role of liposomal doxorubicin in DLBCL lymphomas
Session VIII
Acute leukemia
Chairmen: H. Kantarjian, G. Martinelli
E.M. Stein
IDH2 inhibitors in acute myeloid leukemia
R.M. Stone
FLT3 inhibitors in acute myeloid leukemia
H. Kantarjian
Inotuzumab ozogamicin in acute lymphoblastic leukemia
